NO324750B1 - Substituerte N-benzylindol-3-yl-glyokylinsyrederivater med anti-tumoreffekt, og farmasoytiske preparater som inneholder slike. - Google Patents

Substituerte N-benzylindol-3-yl-glyokylinsyrederivater med anti-tumoreffekt, og farmasoytiske preparater som inneholder slike. Download PDF

Info

Publication number
NO324750B1
NO324750B1 NO20023039A NO20023039A NO324750B1 NO 324750 B1 NO324750 B1 NO 324750B1 NO 20023039 A NO20023039 A NO 20023039A NO 20023039 A NO20023039 A NO 20023039A NO 324750 B1 NO324750 B1 NO 324750B1
Authority
NO
Norway
Prior art keywords
acid
salts
compounds
general formula
indol
Prior art date
Application number
NO20023039A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023039D0 (no
NO20023039L (no
Inventor
Bernd Nickel
Dietmar Reichert
Eckhard Guenther
Gerald Bacher
Guillaume Lebaut
Peter-Paul Emig
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20023039D0 publication Critical patent/NO20023039D0/no
Publication of NO20023039L publication Critical patent/NO20023039L/no
Publication of NO324750B1 publication Critical patent/NO324750B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
NO20023039A 1999-12-23 2002-06-21 Substituerte N-benzylindol-3-yl-glyokylinsyrederivater med anti-tumoreffekt, og farmasoytiske preparater som inneholder slike. NO324750B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962300A DE19962300A1 (de) 1999-12-23 1999-12-23 Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
PCT/EP2000/012947 WO2001047913A2 (de) 1999-12-23 2000-12-19 Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung

Publications (3)

Publication Number Publication Date
NO20023039D0 NO20023039D0 (no) 2002-06-21
NO20023039L NO20023039L (no) 2002-08-09
NO324750B1 true NO324750B1 (no) 2007-12-03

Family

ID=7934006

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023039A NO324750B1 (no) 1999-12-23 2002-06-21 Substituerte N-benzylindol-3-yl-glyokylinsyrederivater med anti-tumoreffekt, og farmasoytiske preparater som inneholder slike.

Country Status (31)

Country Link
US (1) US6432987B2 (cg-RX-API-DMAC7.html)
EP (1) EP1240157B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003519137A (cg-RX-API-DMAC7.html)
KR (1) KR100747425B1 (cg-RX-API-DMAC7.html)
CN (1) CN1283637C (cg-RX-API-DMAC7.html)
AR (1) AR027098A1 (cg-RX-API-DMAC7.html)
AT (1) ATE259364T1 (cg-RX-API-DMAC7.html)
AU (1) AU772745B2 (cg-RX-API-DMAC7.html)
BG (1) BG106924A (cg-RX-API-DMAC7.html)
BR (1) BR0016712A (cg-RX-API-DMAC7.html)
CA (1) CA2395259A1 (cg-RX-API-DMAC7.html)
CO (1) CO5251472A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20022094A3 (cg-RX-API-DMAC7.html)
DE (2) DE19962300A1 (cg-RX-API-DMAC7.html)
DK (1) DK1240157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2215768T3 (cg-RX-API-DMAC7.html)
HK (1) HK1054038B (cg-RX-API-DMAC7.html)
HU (1) HUP0203716A3 (cg-RX-API-DMAC7.html)
IL (1) IL150235A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02006229A (cg-RX-API-DMAC7.html)
NO (1) NO324750B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ533731A (cg-RX-API-DMAC7.html)
PL (1) PL195014B1 (cg-RX-API-DMAC7.html)
PT (1) PT1240157E (cg-RX-API-DMAC7.html)
RU (1) RU2266280C2 (cg-RX-API-DMAC7.html)
SK (1) SK8752002A3 (cg-RX-API-DMAC7.html)
TR (1) TR200400601T4 (cg-RX-API-DMAC7.html)
TW (1) TWI284128B (cg-RX-API-DMAC7.html)
UA (1) UA75060C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001047913A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204896B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
JP4878285B2 (ja) * 2003-06-05 2012-02-15 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング アポトーシス誘発作用を有するインドール誘導体
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセットトランスポーターのモジュレーター
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
CA2670778A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (cg-RX-API-DMAC7.html) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
ES2122555T3 (es) * 1994-02-22 1998-12-16 Merrell Pharma Inc Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
EP1030661A4 (en) * 1997-10-27 2002-07-17 Lilly Co Eli N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
AU1200899A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1039901A1 (en) * 1997-11-14 2000-10-04 Eli Lilly And Company Treatment for alzheimer's disease
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DK1076657T3 (da) * 1998-04-28 2004-11-08 Elbion Ag Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
EA200001140A1 (ru) * 1998-05-01 2001-04-23 Эли Лилли Энд Компани СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action

Also Published As

Publication number Publication date
PT1240157E (pt) 2004-06-30
KR20020063245A (ko) 2002-08-01
RU2266280C2 (ru) 2005-12-20
CO5251472A1 (es) 2003-02-28
CA2395259A1 (en) 2001-07-05
NZ519977A (en) 2004-08-27
ZA200204896B (en) 2002-12-20
AR027098A1 (es) 2003-03-12
PL355684A1 (en) 2004-05-17
US6432987B2 (en) 2002-08-13
WO2001047913A2 (de) 2001-07-05
DE50005284D1 (de) 2004-03-18
IL150235A0 (en) 2002-12-01
PL195014B1 (pl) 2007-07-31
CN1420880A (zh) 2003-05-28
HUP0203716A3 (en) 2004-05-28
BG106924A (bg) 2003-04-30
AU772745B2 (en) 2004-05-06
AU2011901A (en) 2001-07-09
US20010014690A1 (en) 2001-08-16
UA75060C2 (en) 2006-03-15
CN1283637C (zh) 2006-11-08
TWI284128B (en) 2007-07-21
HK1054038B (zh) 2007-04-13
DK1240157T3 (da) 2004-06-14
WO2001047913A3 (de) 2002-04-25
EP1240157B1 (de) 2004-02-11
ES2215768T3 (es) 2004-10-16
RU2002120462A (ru) 2004-01-10
NO20023039D0 (no) 2002-06-21
DE19962300A1 (de) 2001-06-28
MXPA02006229A (es) 2003-01-28
SK8752002A3 (en) 2003-01-09
TR200400601T4 (tr) 2004-04-21
NO20023039L (no) 2002-08-09
BR0016712A (pt) 2002-09-03
HK1054038A1 (en) 2003-11-14
NZ533731A (en) 2005-03-24
EP1240157A2 (de) 2002-09-18
JP2003519137A (ja) 2003-06-17
ATE259364T1 (de) 2004-02-15
HUP0203716A2 (hu) 2003-03-28
KR100747425B1 (ko) 2007-08-09
CZ20022094A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
JP5253696B2 (ja) 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体
US5143916A (en) Naphthylpiperazines useful as 5-ht1a receptor ligands
CZ302301B6 (cs) N-Substituovaný indol-3-glyoxylamid, zpusob jeho prípravy, farmaceutická kompozice obsahující tento glyoxylamid, zpusob výroby léciva obsahujícího tento glyoxylamid a použití tohoto glyoxylamidu pri výrobe léciva
JP3834098B2 (ja) ベンゾニトリル類およびベンゾフルオリド類
EP0370498A2 (en) Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
US6432987B2 (en) Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action
TWI393708B (zh) 異羥肟酸脂化合物,其用途及其之合成方法
US5179108A (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application
GB2261661A (en) Derivatives of poly-4-amino-2-carboxy-1-methyl pyrroles
NO309038B1 (no) Fenylindolforbindelser
US4758559A (en) Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors
KR20010013750A (ko) 3-벤질피페리딘
SK42299A3 (en) N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
CZ286896B6 (en) Process for preparing pharmaceutically acceptable salts of naphthyridone carboxylic acid and intermediates for this preparation
CZ172796A3 (en) 3-substituted 1-arylindole derivatives, their use and pharmaceutical compositions containing thereof
WO1988001270A1 (en) Pyridopyrimidinediones
US5166157A (en) Naphthyl piperazines useful as 5-HT1A receptor ligands
US5272157A (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application
US6627650B2 (en) Indenoindolone compounds
US20090312351A1 (en) Processes for the Preparation of Alfuzosin
KR20090011376A (ko) 5-ht7 수용체에 길항작용을 갖는 신규한 화합물
CZ302588B6 (cs) Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
JPS60136556A (ja) ビスアミジンジフエニル誘導体およびそれらの製法
JPWO1990005723A1 (ja) トランス−4−アミノ(アルキル)−1−ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
KR20090096749A (ko) 트리아자벤조〔a〕나프토〔2,1,8­cde〕아줄렌 유도체, 이의 제조방법 및 이를 함유하는 약제 조성물